Itching in Late Pregnancy: Intrahepatic Cholestasis Explained—Symptoms, Testing, Treatment, and Timing of Delivery
Intense itching in late pregnancy—especially on the palms and soles and worse at night—can be a sign of intrahepatic cholestasis of pregnancy (ICP), a liver condition linked to elevated bile acids and specific fetal risks. ICP is diagnosed with blood tests (total bile acids and liver enzymes), managed with medications and monitoring, and delivery timing is guided by your highest bile acid level.
This guide explains what is normal versus concerning, how ICP is tested and treated, how bile acid thresholds inform fetal surveillance and delivery, the risks to baby and mother, and what to expect postpartum and in future pregnancies. The information reflects guidance from leading organizations including SMFM (2021), RCOG (2022), and ACOG (2021).
Key Takeaways
- Severe itching without a rash in late pregnancy warrants testing for ICP with total serum bile acids and liver enzymes.
- SMFM recommends diagnosing ICP when pruritus is present and bile acids are elevated, commonly using a threshold around 10–19 micromol/L depending on fasting status and lab reference ranges.
- Ursodeoxycholic acid is first-line to reduce itching and improve liver tests; it has not clearly reduced stillbirth in trials and monitoring plus timed delivery remain key.
- Stillbirth risk rises with higher bile acids, especially at or above 100 micromol/L, guiding earlier delivery around 36 weeks per SMFM.
- Most symptoms resolve after birth; recurrence in future pregnancies is common, and follow-up of liver tests postpartum is advised.
- PUPPP and normal stretching itch involve a skin rash or stretch marks and do not raise bile acids; ICP typically has no primary rash.
What is intrahepatic cholestasis of pregnancy (ICP), and how is it different from normal pregnancy itching or PUPPP?
ICP is a pregnancy-specific liver condition causing impaired bile flow and elevated bile acids, leading to intense itching without a primary rash, usually in the third trimester. Unlike normal stretching itch or PUPPP (a benign rash), ICP carries fetal risks and requires blood testing and tailored delivery timing.
- ICP: Pruritus (often palms/soles, worse at night), no primary rash, elevated total bile acids and often ALT/AST; risk of stillbirth increases with higher bile acids.
- Normal pregnancy itch: Mild-to-moderate itch from skin stretching and dryness, often with visible stretch marks; no lab abnormalities or fetal risk.
- PUPPP (pruritic urticarial papules and plaques of pregnancy): Itchy hive-like rash starting in stretch marks on the abdomen and spreading; bile acids normal and no specific fetal risk.
| Feature | ICP | Normal Stretching Itch | PUPPP |
|---|---|---|---|
| Typical timing | 3rd trimester; can start earlier | Any time skin stretches (later pregnancy common) | Late 3rd trimester; more common in first pregnancies |
| Primary skin findings | No primary rash; excoriations from scratching | Dryness, stretch marks | Red papules/plaques in stretch marks; hive-like |
| Itch location | Palms/soles; generalized; worse at night | Abdomen, breasts, thighs | Starts on abdomen, spares umbilicus, may spread |
| Bile acids | Elevated | Normal | Normal |
| Fetal risk | Increased with higher bile acids (especially ≥100 µmol/L) | None specific | None specific |
SMFM notes ICP prevalence of roughly 0.3–0.5% in North America, with variation by ethnicity and geography, while RCOG reports about 0.7% in the UK. Accurate diagnosis matters because outcomes for ICP improve with appropriate monitoring and delivery planning.
What symptoms should prompt testing, and what other conditions can mimic ICP?
Severe or persistent itching without a primary rash—especially on the palms and soles and worse at night—should prompt testing for ICP. Jaundice, dark urine, pale stools, right upper quadrant pain, or fatigue with itch also warrant urgent evaluation.
- Classic ICP symptoms: Generalized pruritus (palms/soles prominent), nocturnal worsening; excoriations from scratching; may have mild jaundice.
- Conditions that can mimic or coexist: PUPPP, atopic eruption of pregnancy, scabies, allergic/contact dermatitis, psoriasis; liver/biliary disease (gallstones, viral hepatitis), medication-induced cholestasis; rarer pregnancy liver disorders (acute fatty liver of pregnancy, HELLP) with systemic symptoms.
Because other liver disorders can be serious, clinicians often check for viral hepatitis and assess for gallbladder disease if there is pain, fever, or marked liver test abnormalities.
How is ICP diagnosed: which labs, bile acid thresholds, and when should tests be repeated?
ICP is diagnosed when a pregnant patient with pruritus has elevated total serum bile acids, typically alongside elevated liver enzymes (ALT/AST) after other causes are excluded. If itching is present and initial bile acids are normal, repeat testing is recommended because bile acids can rise over days to weeks.
- Core labs: Total serum bile acids (TSBA), ALT, AST, bilirubin; consider hepatitis panel if indicated.
- Thresholds: SMFM supports diagnosis with pruritus plus elevated bile acids, commonly using ≥10 µmol/L (fasting) or ≥19 µmol/L (nonfasting) depending on local lab reference ranges.
- Sampling: Nonfasting samples are acceptable in many practices; use the same approach consistently with your lab’s reference intervals.
- Repeat testing: If symptoms persist with normal bile acids, repeat in about 1 week, or sooner if itch worsens; many clinicians recheck bile acids and liver enzymes weekly once ICP is diagnosed.
- Documentation: Management and delivery timing are guided by the highest bile acid value recorded.
RCOG stratifies biochemical severity as 19–39 µmol/L (mild), 40–99 µmol/L (moderate), and ≥100 µmol/L (severe), which correlates with fetal risk. Your care plan will align with your level and overall clinical picture.
How is ICP managed: medications, itch relief options, nutrition, and fetal monitoring?
Treatment centers on symptom relief, monitoring, and timed delivery; ursodeoxycholic acid (UDCA) is first-line to reduce itching and improve liver tests, while fetal surveillance is offered given stillbirth risk. No diet or supplement has been proven to cure ICP.
- Medication: UDCA 10–15 mg/kg/day in divided doses (may increase up to 21 mg/kg/day) improves pruritus and ALT/AST; the PITCHES trial did not show reduced composite perinatal morbidity but did show modest itch improvement.
- Refractory cases: Specialist use of rifampin as adjunct therapy is described in severe, treatment-resistant ICP; monitoring for side effects is required.
- Symptomatic relief: Emollients, cooling/menthol creams, lukewarm oatmeal baths, cotton clothing, and short nails; sedating antihistamines at bedtime may help sleep though they do not lower bile acids.
- Vitamin K: Routine supplementation is not needed; consider evaluation if there is prolonged jaundice or abnormal coagulation.
- Fetal monitoring: ACOG suggests offering antenatal testing (NSTs/BPPs) after viability when delivery would be acted upon for abnormal results; testing does not eliminate sudden risk but adds surveillance.
- Lab follow-up: Many clinicians monitor bile acids and liver enzymes weekly, adjusting frequency to symptoms and gestational age.
Discuss any over-the-counter remedies with your obstetric clinician before use, and avoid herbal supplements that may affect the liver.
When is early delivery recommended, and how do bile acid levels influence timing?
Delivery timing is individualized and primarily based on the highest bile acid level, gestational age, and symptoms. SMFM recommends delivery at 36 weeks for bile acids ≥100 µmol/L, and between 36 and 39 weeks for levels <100 µmol/L, with earlier delivery considered for severe symptoms or prior stillbirth related to ICP.
| Highest bile acids (µmol/L) | Typical delivery window | Notes |
|---|---|---|
| <40 | 36w0d – 39w0d | Many aim toward 38–39 weeks if stable and otherwise low risk. |
| 40–99 | 36w0d – 38w6d | Consider earlier in this range if symptoms worsen or additional risks present. |
| ≥100 | Around 36w0d | SMFM recommends delivery at 36w0d; consider 34–36 weeks if severe symptoms, prior IUFD, or worsening labs. |
RCOG reports that stillbirth risk increases as bile acids rise, with the highest risk at ≥100 µmol/L; this risk appears to rise after 38–39 weeks for moderate levels. Your obstetric team will balance fetal risks with the benefits of continued maturation when scheduling delivery.
What are the risks to the baby and the mother, and how common are complications?
For the baby, ICP is associated with increased risks of stillbirth, meconium-stained amniotic fluid, spontaneous preterm birth, and neonatal unit admission, with risk rising alongside bile acid level. For the mother, symptoms can be severe but usually resolve after birth; there is a higher long-term risk of gallstones and some hepatobiliary disorders.
- Fetal risks: Stillbirth risk is highest when bile acids are ≥100 µmol/L; meconium passage and preterm birth are more frequent in ICP.
- Maternal course: Pruritus can be intense; mild jaundice occurs in a minority; cholestasis typically resolves postpartum.
- Long-term maternal considerations: Increased lifetime risk of gallstone disease and recurrent cholestasis has been reported; postpartum follow-up of liver tests is advised.
Absolute risk varies by bile acid level and gestational age; shared decision-making with up-to-date lab values is essential.
What should you expect postpartum: resolution, breastfeeding, and long-term liver health?
Itching and bile acids usually normalize within days to weeks after delivery, and breastfeeding is safe with ICP and with UDCA use. A postpartum check of liver enzymes and bile acids (often around 6 weeks) is recommended to ensure resolution and to guide any needed liver evaluation.
- Symptom resolution: Pruritus typically improves quickly after birth as bile acids fall.
- Follow-up: Recheck liver enzymes and bile acids at the postpartum visit; persistent abnormalities warrant evaluation.
- Contraception: Estrogen-containing methods can rarely trigger cholestasis; progestin-only or non-hormonal options are often preferred if there was cholestasis with prior estrogen exposure—discuss with your clinician.
- Breastfeeding: Safe in ICP; UDCA is considered compatible with breastfeeding in usual doses.
Will ICP happen again in future pregnancies, and how can you plan ahead?
ICP frequently recurs, with recurrence rates estimated between about 45% and 90% depending on population and severity. Planning ahead includes early discussion with your obstetric team, prompt testing if itching returns, and consideration of baseline liver tests during pregnancy.
- Preconception: Share your ICP history with your clinician; consider screening for underlying liver/biliary risk factors if indicated.
- Early pregnancy: Establish a monitoring plan; report itching promptly, even if mild.
- Lifestyle: There is no proven diet to prevent ICP; avoid unnecessary hepatotoxic supplements and discuss all medications with your clinician.
- Care team: High-risk obstetric consultation may be helpful, especially if you previously had high bile acids or early delivery.
Frequently Asked Questions
Do I need to fast for a bile acid test, and can levels fluctuate?
Your clinician may order either a fasting or nonfasting bile acid test; many practices accept nonfasting samples and interpret them with the lab’s reference ranges. Levels can fluctuate and may rise as pregnancy advances, so repeat testing is recommended if symptoms persist despite an initial normal result.
Does ursodeoxycholic acid treat the baby’s risks or just my itching?
UDCA reliably improves itching and liver enzymes, but the large PITCHES trial did not show a reduction in a composite of adverse perinatal outcomes. Because fetal risk is linked to bile acids and gestational age, surveillance and delivering at the recommended time remain central to care.
How often will I have fetal monitoring with ICP?
ACOG advises offering antenatal testing once the pregnancy is far enough along that abnormal results would prompt delivery, often weekly or twice weekly based on your situation. While testing cannot completely prevent sudden events, it provides additional surveillance and an opportunity to act on concerning signs.
Is cholestyramine helpful for ICP-related itching?
Cholestyramine is generally not first-line for ICP because it can interfere with fat-soluble vitamin absorption and may worsen vitamin K deficiency. UDCA is preferred for symptom relief, with other options considered by specialists if symptoms are refractory.
Does ICP change if I’m carrying twins?
Multiple gestations are associated with higher pregnancy hormone levels and may present with earlier or more severe ICP. Your team may monitor bile acids more closely and consider delivery toward the earlier end of recommended windows depending on levels and symptoms.
Sources
- Society for Maternal-Fetal Medicine (SMFM) — SMFM Consult Series #53: Intrahepatic cholestasis of pregnancy
- Royal College of Obstetricians and Gynaecologists (RCOG) — Obstetric Cholestasis (Green-top Guideline No. 43)
- ACOG — Indications for Outpatient Antenatal Fetal Surveillance
- The Lancet — Ursodeoxycholic acid versus placebo in women with intrahepatic cholestasis of pregnancy (PITCHES): a randomised controlled trial
- NICHD (NIH) — Cholestasis of Pregnancy
- AASLD (Hepatology) — Reproductive health and liver disease: AASLD practice guidance
- ACOG — Skin Conditions During Pregnancy
The views, statements, and pricing expressed are deemed reliable as of the published date. Articles may not reflect current pricing, offerings, or recent innovations.